DIPROLENE (betamethasone dipropionate) by Merck & Co. is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of diprolene ointment in corticosteroid responsive dermatoses is unknown. First approved in 1983.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
DIPROLENE (Betamethasone Dipropionate) is an augmented topical corticosteroid ointment approved in 1983 for corticosteroid-responsive dermatoses. It works by modulating immune function, inflammation signaling, and protein regulation, though its precise mechanism in skin conditions remains incompletely understood. The product is administered topically and is indicated for inflammatory skin conditions.
Product is in late-stage lifecycle with minimal Part D utilization, suggesting a mature brand with limited growth trajectory and likely reduced commercial team size.
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of DIPROLENE Ointment in corticosteroid responsive dermatoses is unknown.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Effect of Intra-sinus Application of Betamethasone Dipropionate Nasal Cream on Patients with Chronic Rhinosinusitis Post Functional Endoscopic Sinus Surgery (FESS)
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.
Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects
Worked on DIPROLENE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on DIPROLENE offers limited career growth due to its mature, approaching-LOE lifecycle and minimal commercial activity (53 Part D claims in 2023). Positions on this product are best suited for professionals managing stable, legacy brands or transitioning toward generic/OTC strategies rather than those seeking high-impact launch or growth experience.